Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Stanton R. Mehr
Authored Items
Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD
Stanton R. Mehr
February 2017 Vol 10, No 1
in
Perspectives
Is a Biologic Produced 15 Years Ago a Biosimilar of Itself Today?
Stanton R. Mehr
,
Marj P. Zimmerman, BSPharm, MS
December 2016 Vol 9, No 9
in
Biosimilars
Will the PCSK9 Inhibitors Be Employers’ “Line in the Sand”?
Stanton R. Mehr
May 2016 Vol 9, No 3
in
Practice Management
Payer Perspectives on PCSK9 Inhibitors
Stanton R. Mehr
February 2016 Vol 9, No 1
in
Original Research
Reviewing the Unmet Needs of Patients with Multiple Sclerosis
Stanton R. Mehr
,
Marj P. Zimmerman, BSPharm, MS
November 2015 Vol 8, No 8
in
Original Research
The Latest Innovations in the Drug Pipeline for Multiple Sclerosis
Lea Radick
,
Stanton R. Mehr
November 2015 Vol 8, No 8
in
Original Research
Last modified: April 14, 2017
